Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- PMID: 30304655
- PMCID: PMC7030948
- DOI: 10.1056/NEJMoa1716614
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Abstract
Background: Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic characterization of patients with myeloproliferative neoplasms offers the potential for personalized diagnosis, risk stratification, and treatment.
Methods: We sequenced coding exons from 69 myeloid cancer genes in patients with myeloproliferative neoplasms, comprehensively annotating driver mutations and copy-number changes. We developed a genomic classification for myeloproliferative neoplasms and multistage prognostic models for predicting outcomes in individual patients. Classification and prognostic models were validated in an external cohort.
Results: A total of 2035 patients were included in the analysis. A total of 33 genes had driver mutations in at least 5 patients, with mutations in JAK2, CALR, or MPL being the sole abnormality in 45% of the patients. The numbers of driver mutations increased with age and advanced disease. Driver mutations, germline polymorphisms, and demographic variables independently predicted whether patients received a diagnosis of essential thrombocythemia as compared with polycythemia vera or a diagnosis of chronic-phase disease as compared with myelofibrosis. We defined eight genomic subgroups that showed distinct clinical phenotypes, including blood counts, risk of leukemic transformation, and event-free survival. Integrating 63 clinical and genomic variables, we created prognostic models capable of generating personally tailored predictions of clinical outcomes in patients with chronic-phase myeloproliferative neoplasms and myelofibrosis. The predicted and observed outcomes correlated well in internal cross-validation of a training cohort and in an independent external cohort. Even within individual categories of existing prognostic schemas, our models substantially improved predictive accuracy.
Conclusions: Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms. Integration of genomic data with clinical variables enabled the personalized predictions of patients' outcomes and may support the treatment of patients with myeloproliferative neoplasms. (Funded by the Wellcome Trust and others.).
Figures
Comment in
-
New Classification for Myeloproliferative Neoplasms.Cancer Discov. 2018 Dec;8(12):OF1. doi: 10.1158/2159-8290.CD-NB2018-144. Epub 2018 Nov 8. Cancer Discov. 2018. PMID: 30409777
Similar articles
-
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.Blood. 2014 Jun 12;123(24):3714-9. doi: 10.1182/blood-2014-03-530865. Epub 2014 Apr 30. Blood. 2014. PMID: 24786775
-
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM. Am J Clin Pathol. 2015. PMID: 25873496
-
Somatic mutations of calreticulin in myeloproliferative neoplasms.N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10. N Engl J Med. 2013. PMID: 24325356
-
[Clinical application of gene mutation information in myeloproliferative neoplasms].Rinsho Ketsueki. 2019;60(6):610-618. doi: 10.11406/rinketsu.60.610. Rinsho Ketsueki. 2019. PMID: 31281152 Review. Japanese.
-
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Acta Haematol. 2015. PMID: 25116092 Review.
Cited by
-
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.Leukemia. 2024 Sep 28. doi: 10.1038/s41375-024-02425-1. Online ahead of print. Leukemia. 2024. PMID: 39341969
-
Advances in Stem Cell Transplantation for Myelofibrosis.Curr Hematol Malig Rep. 2024 Sep 6. doi: 10.1007/s11899-024-00742-x. Online ahead of print. Curr Hematol Malig Rep. 2024. PMID: 39240494 Review.
-
Case report: A case of effective treatment of primary myelofibrosis with nodular panniculitis using ruxolitinib combined with corticosteroids.Front Oncol. 2024 Aug 19;14:1412021. doi: 10.3389/fonc.2024.1412021. eCollection 2024. Front Oncol. 2024. PMID: 39224801 Free PMC article.
-
Combination of ligand‑based and structure‑based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms.Mol Divers. 2024 Aug 29. doi: 10.1007/s11030-024-10938-1. Online ahead of print. Mol Divers. 2024. PMID: 39210217
-
Increased mRNA expression for serotonin receptor 1B (HTR1B) is associated with thrombosis in BCR::ABL1-negative myeloproliferative neoplasms.J Cell Mol Med. 2024 Aug;28(16):e70024. doi: 10.1111/jcmm.70024. J Cell Mol Med. 2024. PMID: 39183370 Free PMC article.
References
-
- Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5. - PubMed
-
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. - PubMed
-
- Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol. 2014;167(3):421–3. - PubMed
-
- McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138(6):821–2. - PubMed
-
- Reilly JT, McMullin MF, Beer PA, et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol. 2014;167(3):418–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous